89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors (STARBURST)

Telix Pharmaceuticals (Innovations) Pty Ltd

Status and phase: Terminated; Phase 2

Conditions: Epithelial Ovarian Cancer; Glioblastoma Multiforme; Esophageal Cancer; Small Cell Lung Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Gastric Adenocarcinoma; Bladder Cancer; Malignant Mesothelioma (MM); Gastric Cancer; Soft Tissue Sarcoma; Nasopharyngeal Carcinoma; Von Hippel Lindau; Hepatocellular Carcinoma; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer

Treatments: Diagnostic Test: 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors

Study type: Interventional

Funder types: Industry

Identifiers

NCT05563272

89Zr-TLX250-005

Details and patient eligibility

About

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Enrollment: 11 patients

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

All participants must meet the following criteria:

1. Written and voluntarily given Informed Consent.

2. Male or female ≥18 years of age at time of consent.

3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements.

4. Participants must have proven tumors of the following types, but not limited to:

   • Cervical cancer;
   • Colorectal cancer;
   • Esophageal SCC and esophageal/esophagogastric junction adenocarcinoma;
   • Gastric adenocarcinoma;
   • GBM;
   • Head and neck SCC and nasopharyngeal carcinoma;
   • cholangiocarcinoma and hepatocellular carcinoma;
   • non-small cell lung cancer;
   • small cell lung cancer;
   • epithelial ovarian carcinoma;
   • pancreatic ductal adenocarcinoma;
   • Soft tissue sarcoma;
   • malignant mesothelioma;
   • confirmed diagnosis of VHL disease with VHL germline alteration and at least one VHL-related lesion.

5. Have at least one non-central nervous system (CNS), measurable target lesion as defined per RECIST 1.1 and documented by SOC conventional imaging, performed within 60 days (+14 days) prior to Day 0 (excepting participants with GBM or hemangioblastoma, given that all lesions may be in the CNS, such lesions assessed by RANO);

6. Have agreed not to receive another investigational product while participating in the present study, defined as signing the informed consent form (ICF), until completion of the last study visit;

7. Have negative serum pregnancy tests if a female of childbearing potential at screening and have a confirmatory negative urine pregnancy test result within 24 hours prior to receiving investigational product. Female participants of non-child- bearing potential must provide evidence by fulfilling one of the following criteria at screening:

   • Be post-menopausal, defined as more than 50 years of age and amenorrheic for at least 12 months since cessation of all exogenous hormonal treatments;
   • Be a woman under 50 years of age and considered postmenopausal given amenorrhea for 12 months or more since cessation of exogenous hormonal treatments and having luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range by institutional SOC;
   • Have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation; and

8. Have consented to practice highly effective method of contraception until a minimum of 42 days after 89Zr-girentuximab administration

Exclusion Criteria

Participants will be excluded from participation in the study if one or more of the following criteria are met:

1. Have been administered any radionuclide within 10 half-lives (of the radionuclide) prior to the intended administration of 89Zr-girentuximab (i.e., within 10 half-lives of Day 0);
2. Have been exposed to any CAIX targeting compound (diagnostic/therapeutic) in the prior 3 months;
3. Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator;
4. Have any clinically significant abnormalities detected during screening laboratory tests or physical exam that, in the opinion of the Investigator, would adversely affect the participant's ability to participate in the study;
5. Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study;
6. Have been exposed to any antineoplastic treatment from Day 0 (89Zr-girentuximab dosing) to completion of 89Zr-girentuximab PET/CT imaging (Day 5 ± 2 days);
7. Be a female who is pregnant or breastfeeding;
8. Have a known allergy, hypersensitivity, or intolerance to girentuximab, desferrioxamine (DFO), or any of the components of the investigational agent;
9. Have renal insufficiency with a glomerular filtration rate (GFR) ≤45 milliliters/min/1.73m2
10. Be a vulnerable participant (e.g., being in detention).

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 1 patient group

89Zr-TLX250

Experimental group

Treatment:

Diagnostic Test: 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors